| Literature DB >> 28594891 |
Lucy A Parker1,2, John Rumunu3, Christine Jamet1, Yona Kenyi3, Richard Laku Lino3, Joseph F Wamala4, Allan M Mpairwe4, Vincent Muller1, Augusto E Llosa5, Florent Uzzeni1, Francisco J Luquero5,6, Iza Ciglenecki1, Andrew S Azman1,7.
Abstract
INTRODUCTION: In June 2015, a cholera outbreak was declared in Juba, South Sudan. In addition to standard outbreak control measures, oral cholera vaccine (OCV) was proposed. As sufficient doses to cover the at-risk population were unavailable, a campaign using half the standard dosing regimen (one-dose) targeted high-risk neighborhoods and groups including neighbors of suspected cases. Here we report the operational details of this first public health use of a single-dose regimen of OCV and illustrate the feasibility of conducting highly targeted vaccination campaigns in an urban area. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2017 PMID: 28594891 PMCID: PMC5478158 DOI: 10.1371/journal.pntd.0005652
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Fig 1Overview of vaccination areas in Juba.
Sub-panel on top left illustrates the case-triggered comprehensive targeted intervention (CTI) approach.
Population size and vaccine coverage estimates for neighborhood-targeted vaccination campaign.
| Received OCV | Population estimate from census | Population estimate from satellite images | Population-based survey | |||
|---|---|---|---|---|---|---|
| Doses | N | Administrative Vaccine Coverage | N | Administrative Vaccine Coverage | Vaccine Coverage | |
| 91,953 | 48,470 | 190 | 126,540 | 73 | 70(63–77) | |
| 21,039 | 906 | 2322 | 19,425 | 108 | 60(52–68) | |
| 27,257 | 4,167 | 654 | 38,103 | 72 | 69(63–75) | |
| 140,249 | 53,543 | 262 | 184,068 | 76 | 69(64–74) | |
1 Number of people who received OCV in each target based on tally sheets from each vaccination team
2 The population estimates generated from the most recent census were considered to vastly underestimate the true number of inhabitants so digital satellite images were used to provide alternative estimates allowing a more conservative planning. Estimates were calculated using the number of built structures divided by 2 (mean number of structures per household from survey) and multiplied by 6 (est. number of individuals per household)
3 Calculated by dividing the number of vaccines distributed by the estimated population size. Tally sheets were used to record the number of people vaccinated at each site per sex and age group (1–4 years, 5–14 years, 15 years and over)
4Individuals were considered vaccinated regardless of whether they had a vaccination card.
5Settlement did not officially exist at the time of the 2008 census
Number of people who received OCV by age category and sex based on tally sheets from each vaccination team; and estimated vaccine coverage.
| Male | Female | Total | Vaccine Coverage | |
|---|---|---|---|---|
| N (%) | N (%) | N | % (95%CI) | |
| 1–4 years | 11,170 (50.4) | 10,975 (49.6) | 22,145 | 79(72–86) |
| 5–15 years | 20,931 (49.3) | 21,535 (50.7) | 42,466 | 90(86–94) |
| ≥15 years | 39,844 (52.7) | 35,794 (47.3) | 75,638 | 53(46–59) |
| Total | 71,945 (51.3) | 68,304 (48.7) | 140,249 | 69(64–74) |
| 1–4 years | 2,029 (51.0) | 2,062 (49.0) | 4,091 | 65(50–80) |
| 5–15 years | 3,943 (50.0) | 3,943 (50.0) | 7,886 | 68(57–79) |
| ≥15 years | 3,660 (53.6) | 5,486 (46.4) | 9,146 | 43(33–52) |
| Total | 9,632 (51.9) | 11,491 (48.1) | 21,123 | 51(42–60) |
1From population-based survey. Individuals were considered vaccinated regardless of whether they had a vaccination card.
Fig 2Selection of households for inclusion in the neighborhood-targeted vaccine coverage survey.
Fig 3Estimated vaccine coverage by distance to the closest vaccination site in the neighborhood-targeted campaign.
Line represents LOESS smoothed estimates of coverage with non-parametric 95% confidence intervals.
Fig 4Estimated vaccine coverage by age and sex in the neighborhood-targeted campaign.
Red represents women and blue represents men. Lines represent LOESS smoothed estimates of coverage by sex and non-parametric 95% confidence intervals.